Quantcast

Phase I Study Results Show First-in-class NBTXR3 Could Present as a Valuable Option for Patients With Hepatocellular Carcinoma or Liver Metastasis

Nanobiotix’s radioenhancer NBTXR3 study showed encouraging results for Hepatocellular Carcinoma (HCC) patients, which are significant as they increase the scope of patients NBTXR3 may treat beyond Soft Tissue Sarcoma and Head and Neck cancer. 

Read more

NICE recommends Takhzyro injection as an option for preventing recurrent attacks of hereditary angioedema (HAE)

NICE has recommended the use of Takhzyro subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, within their final appraisal document (FAD), Takeda UK said in a press release Wednesday.

Read more

Onxeo encouraged by intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA in combination with chemotherapy

Onxeo said it stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ plus carboplatin, with reaching satisfactory tolerance allowing the continuation of the study to evaluate AsiDNA™ in combination with carboplatin and paclitaxel, a reference treatment protocol for many cancers.

Read more